ECSP088262A - ALBUMIN FUSION PROTEINS - Google Patents

ALBUMIN FUSION PROTEINS

Info

Publication number
ECSP088262A
ECSP088262A EC2008008262A ECSP088262A ECSP088262A EC SP088262 A ECSP088262 A EC SP088262A EC 2008008262 A EC2008008262 A EC 2008008262A EC SP088262 A ECSP088262 A EC SP088262A EC SP088262 A ECSP088262 A EC SP088262A
Authority
EC
Ecuador
Prior art keywords
albumin fusion
fusion proteins
vectors
host cells
methods
Prior art date
Application number
EC2008008262A
Other languages
Spanish (es)
Inventor
Craig Rosen
Adam Bell
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of ECSP088262A publication Critical patent/ECSP088262A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención comprende proteínas de fusión de albúmina. Las moléculas de ácido nucleicoque codifican las proteínas de fusión de albúmina de la invención también están comprendidas en la invención, así como los vectores que contienen estos ácidos nucleicos, las células hospederas transformadas con estos vectores de ácidos nucleicos, y los métodos de hacer las proteínas de fusión de albúmina de la invención y de usar estos ácidos nucleicos, vectores, y/o células hospederas. Adicionalmente, la presente invención incluye composiciones farmacéuticas que comprenden las proteínas de fusión de albúmina y los métodos de tratamiento, prevención o mejoramiento de las enfermedades, trastornos o condiciones utilizando las proteínas de fusión de albúmina de la invención.The present invention comprises albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also included in the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acid vectors, and methods of making proteins. albumin fusion of the invention and using these nucleic acids, vectors, and / or host cells. Additionally, the present invention includes pharmaceutical compositions comprising albumin fusion proteins and methods of treatment, prevention or improvement of the diseases, disorders or conditions using the albumin fusion proteins of the invention.

EC2008008262A 2005-08-12 2008-03-12 ALBUMIN FUSION PROTEINS ECSP088262A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15

Publications (1)

Publication Number Publication Date
ECSP088262A true ECSP088262A (en) 2008-05-30

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008262A ECSP088262A (en) 2005-08-12 2008-03-12 ALBUMIN FUSION PROTEINS

Country Status (13)

Country Link
EP (1) EP1924596A4 (en)
JP (1) JP2009504157A (en)
KR (1) KR20080071119A (en)
AU (1) AU2006280312A1 (en)
BR (1) BRPI0614761A2 (en)
CA (1) CA2618476A1 (en)
EC (1) ECSP088262A (en)
IL (1) IL189246A0 (en)
MA (1) MA29836B1 (en)
MX (1) MX2008001865A (en)
NO (1) NO20081233L (en)
TN (1) TNSN08064A1 (en)
WO (1) WO2007021494A2 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSED PROTEINS
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
PT1463751E (en) 2001-12-21 2013-08-26 Human Genome Sciences Inc ALBUMINE FUSION PROTEINS
JP5010923B2 (en) 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Albumin fusion protein
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007258609B2 (en) * 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2663352A1 (en) * 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP2423219B1 (en) 2007-01-30 2015-04-29 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
BRPI0915093A2 (en) 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugates for the administration of biologically active compounds
MX2011007583A (en) * 2009-01-16 2011-12-14 Teva Pharma New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein.
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
KR20100100254A (en) * 2009-03-05 2010-09-15 (주)바이오큐어팜 Composition for preventing or treating cancer comprising human serum albumin-timp-2 fusion protein and anti-cancer agent
CN102741275B (en) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 Plasma thromboplastin component compositions and preparation and application thereof
CN102741280B (en) * 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 Albumin variants
CN106977608A (en) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 Albumin derivant and variant
ES2674567T3 (en) * 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Bispecific Fusion Proteins
WO2012118042A1 (en) * 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター Medicinal agent for inhibiting metastasis of malignant tumor
MX353816B (en) 2011-05-05 2018-01-30 Albumedix As Albumin variants.
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (en) 2011-10-21 2014-09-03 艾伯维公司 Combination therapy with one or more DAAs used to treat HCV (eg, with ABT-072 or ABT-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
EP2804623B1 (en) 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT3564260T (en) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
MX2014010278A (en) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Albumin variants.
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc CHIMERIC COAGULATION FACTORS
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CN103525695B (en) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 Portable kidney function detecting system
CN110054699A (en) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 Factor IX compound with XTEN and vWF ELISA albumen, and application thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
FI3889173T3 (en) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimized factor viii gene
WO2014125082A1 (en) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
TWI828269B (en) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 Factor ix polypeptide formulations
MX2015016567A (en) 2013-06-28 2016-03-31 Biogen Ma Inc Thrombin cleavable linker with xten and its uses thereof.
TWI667255B (en) 2013-08-14 2019-08-01 美商生物化學醫療公司 Factor viii-xten fusions and uses thereof
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
BR112017007765B1 (en) 2014-10-14 2023-10-03 Halozyme, Inc COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING THE SAME
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods for their preparation and use
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
CN105254766B (en) * 2015-10-26 2018-10-16 中国航天员科研训练中心 Application of the Mecano growth factor MGF E domain peptides in regulation and control memory related gene and miRNA expression
KR20180118659A (en) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. Optimized Factor VIII Factor
JP7129703B2 (en) 2016-04-28 2022-09-02 エモリー ユニバーシティー Alkyne-Containing Nucleotide and Nucleoside Therapeutic Compositions and Uses Associated Therewith
JP2020500306A (en) 2016-11-04 2020-01-09 オーフス ウニベルシテット Identification and treatment of tumors characterized by neonatal Fc receptor overexpression
JP2019536794A (en) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド Methods for inducing immune tolerance to coagulation factors
MX2019006444A (en) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc HEMOPHILIC ARTHROPATHY TREATMENT METHODS USING CHEMERIC COAGULATION FACTORS.
WO2018112362A1 (en) 2016-12-16 2018-06-21 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
WO2018144623A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
MA50141A (en) * 2017-04-20 2020-07-29 Novo Nordisk As ALBUMIN FUSION PROTEIN PURIFICATION PROCESSES
BR112020002394A2 (en) 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. nucleic acid molecules and uses thereof
AU2019215063B2 (en) 2018-02-01 2025-10-16 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
SI3793588T1 (en) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
AU2019297327A1 (en) 2018-07-03 2021-02-18 Bristol-Myers Squibb Company FGF21 formulations
KR102925832B1 (en) 2018-08-09 2026-02-11 바이오버라티브 테라퓨틱스 인크. Nucleic acid molecules and their use in non-viral gene therapy
BR112021010047A2 (en) 2018-12-06 2021-08-24 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
KR20230074703A (en) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. Method for removing free factor VIII from preparations of lentiviral vectors modified to express the protein
WO2022030580A1 (en) * 2020-08-06 2022-02-10 国立大学法人宮崎大学 Novel long-acting adrenomedullin derivative, method for producing same and pharmaceutical use thereof
US12487299B2 (en) 2022-06-20 2025-12-02 Shanghai United Imaging Healthcare Co., Ltd. Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices
JP2024056667A (en) * 2022-10-11 2024-04-23 Ｊｃｒファーマ株式会社 Fusion protein of serum albumin and a biologically active protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1463751E (en) * 2001-12-21 2013-08-26 Human Genome Sciences Inc ALBUMINE FUSION PROTEINS
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
JP5010923B2 (en) * 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Albumin fusion protein
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
NO20081233L (en) 2008-05-09
EP1924596A2 (en) 2008-05-28
AU2006280312A1 (en) 2007-02-22
WO2007021494A3 (en) 2007-07-26
TNSN08064A1 (en) 2009-07-14
KR20080071119A (en) 2008-08-01
MX2008001865A (en) 2008-04-15
BRPI0614761A2 (en) 2009-05-19
CA2618476A1 (en) 2007-02-22
MA29836B1 (en) 2008-10-03
EP1924596A4 (en) 2009-07-29
WO2007021494A2 (en) 2007-02-22
IL189246A0 (en) 2008-08-07
JP2009504157A (en) 2009-02-05

Similar Documents

Publication Publication Date Title
TNSN08064A1 (en) Albumin fusion proteins
MX2009002816A (en) Albumin fusion proteins.
CY1117401T1 (en) ALBUMIN Fusion Proteins
JOP20190083B1 (en) FGF21 fusion polypeptides and their uses
WO2005003296A3 (en) Albumin fusion proteins
ATE483027T1 (en) RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROKARYONTIC CELLS
DOP2018000245A (en) GDF15 FUSION PROTEINS AND USES OF THESE
HN2006016512A (en) ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
MA32771B1 (en) FGF21 MUTANTS AND USES THEREOF
BR112019005587A2 (en) recombinant binding proteins and their use
UY29344A1 (en) HUMANIZED ANTIAMILOID ANTIBODIES
EA201001204A1 (en) METHODS AND COMPOSITIONS IN WHICH APPLY KLOTHO-FGF POLYPEPTIDES FUSED
CY1114265T1 (en) ALBUMIN Fusion Protein
CY1110860T1 (en) REVERSE TRANSLATION OF Poultry Telomerase
CR8978A (en) UNION DOMAIN FUSION PROTEINS
BRPI0511118A (en) untranscribed haemophilus influenzae polypeptides
MX362981B (en) Artificial nucleic acid molecules for improved protein or peptide expression.
BR112017020986A2 (en) recombinant binding proteins and their use
PE20160718A1 (en) MUTANT POLYPEPTIDES FGF21
MX2009004243A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use.
EA201391632A1 (en) AMINO ACID SEQUENCES ARE DIRECTED AGAINST IL-17A, IL-17F AND / OR IL-17A / F AND CONTAINING THEIR POLYPEPTIDES
MX2024012898A (en) TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS, ASSOCIATED FORMULATIONS AND USES THEREOF
ATE533837T1 (en) MICROGININ-PRODUCING PROTEINS AND NUCLEIC ACIDS ENCODING A MICROGININ GENE CLUSTER AND METHODS FOR PRODUCING MICROGININS
ATE439443T1 (en) NEW Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF
UY29544A1 (en) TREATMENT OF DISEASES USING AN IMPROVED REGULATED EXPRESSION SYSTEM